

AVAILABILITY OF THE 2020 UNIVERSAL REGISTRATION DOCUMENT

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

The 2020 Universal Registration Document is available to the public, free of charge under the conditions provided by applicable regulations and may be consulted on the “Investors” page of the Group’s website (www.vetoquinol.com), in the “Regulated Information” section. It is also available on the AMF’s website (www.amf-france.org).

The 2020 Universal Registration Document includes:

- the 2020 Annual Financial Report;
- the Management Report;
- the Board of Directors Report on Corporate Governance;
- the Extra-Financial Performance Declaration;
- the information related to the fees paid to the Statutory Auditors;
- the share buyback program description; and
- the agenda and draft resolutions of the Shareholder’s Meeting of May 27th, 2021.

FOR MORE INFORMATION,
CONTACT:

VETOQUINOL

Investor Relations

Fanny Toillon

Tel.: +33 (0)3 84 62 59 88

relations.investisseurs@vetoquinol.com

Next update: Shareholders’ meeting, May 27th, 2021

KEIMA COMMUNICATION

Investor & Media Relations

Emmanuel Dovergne

Tel.: +33 (0) 1 56 43 44 63

emmanuel.dovergne@keima.fr

ABOUT VETOQUINOL

Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.

As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vetoquinol has been pursuing a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At December 31st 2020, Vetoquinol employs 2,409 people.

Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

